Expanded access program of idebenono [Raxone] in patients with Leber's Hereditary Optic Neuropathy

Trial Profile

Expanded access program of idebenono [Raxone] in patients with Leber's Hereditary Optic Neuropathy

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 May 2016

At a glance

  • Drugs Idebenone (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Therapeutic Use
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2015 According to a Santhera Pharmaceuticals media release, in May 2014, Santhera re-filed a Marketing Authorization Application for idebenone [Raxone] to treat Leber's Hereditary Optic Neuropathy (LHON) with efficacy data from the pivotal RHODOS study (see profile 700227741) and additional clinical efficacy data from this expanded access program.
    • 05 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top